My thoughts entirely. Whatever we might get in return, the FDA are effectively handing us a gigantic invoice. The only questions are a) how gigantic? and b) how do we pay?
If it’s solely via cap raises, then we must be dangerously close to having to conclude that nobody is interested in this for a reason we retailers just cannot see (e.g a problem with the supply agreement, or IP, or whatever it might be. If that’s the case, the SOI will have to multiply for us to see trials through, and that’s more or less a death knell for many retailers hopes of PARs all-time-high share prices being in the future rather than the rear view mirror.
There has to be some plan in place for financing, a deal or something, anything, hot on the heels of an FDA amber or green light. If there isn’t, then it could get really ugly really quickly.
- Forums
- ASX - By Stock
- PAR
- PAR. SP
PAR. SP, page-1134
-
- There are more pages in this discussion • 119 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
Add PAR (ASX) to my watchlist
(20min delay)
|
|||||
Last
20.0¢ |
Change
-0.015(6.98%) |
Mkt cap ! $70.04M |
Open | High | Low | Value | Volume |
21.0¢ | 21.0¢ | 20.0¢ | $201.6K | 994.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
15 | 429247 | 20.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
21.0¢ | 13806 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
15 | 429247 | 0.200 |
9 | 143607 | 0.195 |
17 | 238789 | 0.190 |
4 | 92160 | 0.185 |
8 | 122773 | 0.180 |
Price($) | Vol. | No. |
---|---|---|
0.210 | 13806 | 2 |
0.215 | 28509 | 1 |
0.220 | 59615 | 6 |
0.225 | 28604 | 2 |
0.230 | 16334 | 2 |
Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |